Methotrexate
Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.
Methotrexate may increase skin cancer risk in patients with psoriasis
Psoriasis patients taking methotrexate are nearly three times as likely to develop nonmelanoma skin cancer compared with those not taking the drug, according to a study.
Trial results show gout therapy of pegloticase, methotrexate maintained eGFR vs. placebo
AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.
Methotrexate, low-dose prednisone aids hair regrowth in patients with alopecia subtypes
Methotrexate and low-dose prednisone combination outperformed methotrexate alone in patients with chronic and recalcitrant alopecia totalis and alopecia universalis, according to a study.
Long-term sarilumab demonstrates no new safety concerns in rheumatoid arthritis
Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.
Methotrexate plus pegloticase superior to pegloticase alone in gout
Adding methotrexate to pegloticase increased treatment response, compared with pegloticase alone, in patients with uncontrolled gout, according to data published in Arthritis & Rheumatology.
Study raises questions about value of high-dose methotrexate for young patients with ALL
NEW ORLEANS — A shorter initial course of higher-dose dexamethasone failed to reduce toxicity vs. the standard regimen among children and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma, according to study results.
FDA accepts abbreviated BLA for Biogen’s tocilizumab biosimilar
The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.
Switching from adalimumab to upadacitinib demonstrates clinical improvement for patients with RA
PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.
'Strange times’: Prescribing methotrexate legally ‘low risk’ Post-Roe
PHILADELPHIA — Rheumatologists are unlikely to be held liable under a state’s anti-abortion laws for prescribing methotrexate for a rheumatic disease, according to a law professor who spoke at ACR Convergence 2022.